文献速递衰弱、肌少症与跌倒老年慢病共病管理

强化生活方式与二甲双胍干预对糖尿病预防计划结局研究中衰弱的影响

Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2021-01-01

本研究基于糖尿病预防计划(DPP)临床试验及其结局研究(DPPOS)的长期随访,纳入DPPOS第8年(n=2385)和第10年(n=2289)完成衰弱评估的 participant,比较强化生活方式(ILS)、二甲双胍与安慰剂三组间衰弱的 odds。

要点

  • DPPOS第8年和第10年,ILS组衰弱患病率分别为3.0%和3.6%,低于安慰剂组(5.7%和5.4%)和二甲双胍组(5.4%和5.3%)。
  • 校正访视年份后,ILS相比安慰剂和二甲双胍的衰弱 odds 分别降低38%和37%,二甲双胍与安慰剂无差异。
  • 在平均约50岁时早期启动ILS干预,可能降低日后衰弱患病率;二甲双胍可能对降低衰弱无效。

核心结论

  • 在糖尿病高风险人群中,早期强化生活方式干预与长期随访中较低的衰弱 odds 相关,二甲双胍可能对降低衰弱无效。

研究设计与样本

  • 研究为糖尿病预防计划(DPP)临床试验及其结局研究(DPPOS)的长期随访分析,样本为DPPOS第8年(n=2385)和第10年(n=2289)完成衰弱评估的 participant。

主要发现

  • DPPOS第8年衰弱患病率:ILS组3.0%、二甲双胍组5.4%、安慰剂组5.7%;第10年:ILS组3.6%、二甲双胍组5.3%、安慰剂组5.4%。
  • ILS相比二甲双胍和安慰剂,衰弱 vs 非衰弱的 odds 降低37%。

关键数值与推荐

  • 衰弱采用Fried衰弱表型标准分类,结局为衰弱和衰弱前期 vs 非衰弱。
  • GEE模型校正访视年份,重复测量汇总第8年和第10年数据,估计组间两两OR。

临床怎么用

  • 对糖尿病高风险的中老年人,早期启动强化生活方式干预可能有助于降低日后衰弱风险,临床可考虑将生活方式干预纳入衰弱预防策略。

局限性

  • 研究为DPP/DPPOS的事后分析,原文未报告生活方式干预的具体内容、依从性及衰弱评估的详细流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is a geriatric syndrome of decreased physiologic reserve and resistance to stressors that results in increased vulnerability to adverse health outcomes with aging. Diabetes and hyperglycemia are established risk factors for frailty. We sought to examine whether the odds of frailty among individuals at high risk of diabetes randomized to treatment with intensive lifestyle (ILS), metformin, or placebo differed after long-term follow-up. METHOD: The sample comprised participants in the Diabetes Prevention Program (DPP) clinical trial, who continued follow-up in the DPP Outcomes Study (DPPOS) and completed frailty assessments in DPPOS Years 8 (n = 2385) and 10 (n = 2289), approximately 12 and 14 years after DPP randomization. Frailty was classified using Fried Frailty Phenotype criteria. GEE models adjusting for visit year with repeated measures pooled for Years 8 and 10 were used to estimate pairwise odds ratios (ORs) between ILS, metformin, and placebo for the outcomes of frail and prefrail versus nonfrail. RESULTS: Frailty prevalence by treatment group was ILS = 3.0%, metformin = 5.4%, placebo = 5.7% at Year 8, and ILS = 3.6%, metformin = 5.3%, placebo = 5.4% at Year 10. Odds ratios (95% CI) estimated with GEE models were ILS versus placebo, 0.62 (0.42-0.93), p = .022; metformin versus placebo, 0.99 (0.69-1.42), p = .976; and ILS versus metformin, 0.63 (0.42-0.94), p = .022. Odds of being frail versus nonfrail were 37% lower for ILS compared to metformin and placebo. CONCLUSIONS: Early ILS intervention, at an average age of about 50 years, in persons at high risk of diabetes may reduce frailty prevalence in later life. Metformin may be ineffective in reducing frailty prevalence. CLINICAL TRIALS REGISTRATION NUMBERS: NCT00004992 (DPP) and NCT00038727 (DPPOS).

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Hazuda HP, Pan Q, Florez H, et al. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study. J Gerontol A Biol Sci Med Sci. 2021. PMID: 33428709. doi:10.1093/gerona/glaa295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。